We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
- Authors
Lash, Timothy L; Cronin-Fenton, Deirdre; Ahern, Thomas P; Rosenberg, Carol L; Lunetta, Kathryn L; Silliman, Rebecca A; Hamilton-Dutoit, Stephen; Garne, Jens Peter; Ewertz, Marianne; Sørensen, Henrik Toft; Pedersen, Lars
- Abstract
Up to one-quarter of breast cancer patients suffer clinically significant depression in the year after diagnosis, which may respond to intervention. About half may be prescribed a psychotropic medication, such as a selective serotonin reuptake inhibitor (SSRI), while completing breast cancer therapy. Cytochrome P-450 2D6 (CYP2D6) metabolizes SSRIs and also metabolizes tamoxifen to more active forms. Therefore, concurrent use of SSRIs may reduce tamoxifen's effectiveness at preventing breast cancer recurrence. The SSRI citalopram has limited potency to inhibit CYP2D6 activity, so has been recommended for breast cancer patients taking tamoxifen. This study provides epidemiologic evidence to support this recommendation.
- Publication
Acta oncologica (Stockholm, Sweden), 2010, Vol 49, Issue 3, p305
- ISSN
1651-226X
- Publication type
Journal Article
- DOI
10.3109/02841860903575273